- Home
- DOMH vs GLTO Comparison
DOMH vs GLTO Comparison
Compare DOMH & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- GLTO
- Stock Information
- Founded
- DOMH 1967
- GLTO 2011
- Country
- DOMH United States
- GLTO Denmark
- Employees
- DOMH N/A
- GLTO N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- GLTO Health Care
- Exchange
- DOMH Nasdaq
- GLTO Nasdaq
- Market Cap
- DOMH 83.3M
- GLTO 4.5M
- IPO Year
- DOMH N/A
- GLTO 2020
- Fundamental
- Price
- DOMH $5.10
- GLTO $3.25
- Analyst Decision
- DOMH
- GLTO Buy
- Analyst Count
- DOMH 0
- GLTO 1
- Target Price
- DOMH N/A
- GLTO $10.00
- AVG Volume (30 Days)
- DOMH 297.5K
- GLTO 14.4K
- Earning Date
- DOMH 08-07-2025
- GLTO 08-11-2025
- Dividend Yield
- DOMH 6.31%
- GLTO N/A
- EPS Growth
- DOMH N/A
- GLTO N/A
- EPS
- DOMH N/A
- GLTO N/A
- Revenue
- DOMH $24,891,000.00
- GLTO N/A
- Revenue This Year
- DOMH N/A
- GLTO N/A
- Revenue Next Year
- DOMH N/A
- GLTO N/A
- P/E Ratio
- DOMH N/A
- GLTO N/A
- Revenue Growth
- DOMH 630.80
- GLTO N/A
- 52 Week Low
- DOMH $0.83
- GLTO $2.01
- 52 Week High
- DOMH $13.58
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- DOMH 47.03
- GLTO 46.52
- Support Level
- DOMH $5.08
- GLTO $3.10
- Resistance Level
- DOMH $6.08
- GLTO $3.65
- Average True Range (ATR)
- DOMH 0.53
- GLTO 0.24
- MACD
- DOMH -0.06
- GLTO -0.01
- Stochastic Oscillator
- DOMH 12.50
- GLTO 31.27
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.